DELRAY BEACH, Fla., July 28, 2026 /PRNewswire/ -- According to MarketsandMarkets, the Antibody Therapeutics Market is projected to reach USD 597.1 billion by 2035 from USD 311.2 billion in 2026, at a CAGR of 7.5% during the forecast period.
Browse 400 market data tables and 55 figures spread through 400 pages and an in-depth TOC on the "Antibody Therapeutics Market - Global Forecast to 2035"
Antibody Therapeutics Market Size & Forecast:
- Market Size Available for Years: 2026-2035
- 2026 Market Size: USD 311.2 billion
- 2035 Projected Market Size: USD 597.1 billion
- CAGR (2026-2035): 7.5%
Antibody Therapeutics Market Trends & Insights:
- The fundamental shift from conventional small-molecule drugs toward targeted biologics is transforming the antibody therapeutics market. Over the 2026-2031 period, monoclonal antibodies will remain the commercial foundation that dominated the market in 2025, while the industry increasingly expands into bispecific and multispecific antibodies, antibody-drug conjugates, antibody fragments, and other engineered formats. These next-generation modalities can combine multiple mechanisms, improve target selectivity, and address resistance to established therapies.
- North America held ~35% of the global market in 2025.
- In 2025, monoclonal antibodies dominated the format segment with a share of ~85%, supported by their large, approved product base, broad clinical use across oncology, autoimmune, inflammatory, ophthalmic, and rare disease indications, and strong physician adoption.
- In 2025, hospitals & specialty care centers accounted for ~78% of the market, supported by their central role in diagnosing and treating oncology, autoimmune, inflammatory, ophthalmic, and rare diseases.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=178852478
Key drivers of market growth include rising demand for antibody-based drugs to treat cancer, autoimmune, inflammatory, ophthalmic, and rare diseases, along with rapid progress in next-generation formats such as monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs).
Technological advances in antibody engineering, target discovery, conjugation chemistry, and biomarker-led patient selection are improving efficacy, safety, and clinical differentiation. The late-stage antibody pipeline has expanded significantly, with many antibody therapeutics in late-stage development by 2026, indicating strong innovation momentum. Growth is also supported by expanding investment in bispecific antibodies and ADCs.
By format, the monoclonal antibodies accounted for the largest share of the market in 2025.
By format, the antibody therapeutics market is categorized into monoclonal antibodies, polyclonal antibodies, antibody fragments, bispecific antibodies, and ADCs. In 2025, the monoclonal antibodies segment accounted for the largest share of the market, supported by its large, approved product base, broad clinical use, and strong commercial adoption across oncology, autoimmune diseases, inflammatory disorders, infectious diseases, and other chronic conditions.
In 2025, the hospitals & specialty care centers segment accounted for the largest share of the antibody therapeutics market.
By end user, the antibody therapeutics market includes hospitals & specialty care centers, long-term care facilities, and other end users. In 2025, the hospitals & specialty care centers segment accounted for the largest share of the market. The growth of the hospitals & specialty care centers segment is attributed to the increasing use of antibody therapeutics across oncology, autoimmune diseases, inflammatory disorders, ophthalmology, and rare diseases. These facilities play a critical role in administering complex biologics such as monoclonal antibodies, bispecific antibodies, ADCs, and other next-generation antibody formats that often require specialist supervision, infusion or injectable delivery, and close patient monitoring.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=178852478
By region, North America accounted for the largest share of the market in 2025.
In 2025, North America accounted for the largest share of the antibody therapeutics market, owing to the presence of strong regional players with advanced manufacturing capabilities and robust supply-chain networks. These companies benefit from product approvals under supportive regulatory frameworks implemented by the US FDA and Health Canada. Product commercialization and innovation are the primary catalysts for growth in the region's expanding pharmaceutical & biotechnology industry. Partnerships and investments with academic & research centers to scale up production are also expected to be growth drivers for this regional segment.
Key Players
Leading players in the Antibody Therapeutics companies include AbbVie Inc. (US), Merck (US), Novartis AG (Switzerland), Bristol-Myers Squibb (US), Johnson & Johnson (US), F. Hoffmann-La Roche Ltd. (Switzerland), Sanofi (France), Amgen Inc. (US), Regeneron Pharmaceuticals Inc. (US), and Boehringer Ingelheim International GmbH (Germany), among others.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=178852478
Browse Adjacent Market: Pharmaceuticals Market Research Reports &Consulting
See More Latest Pharmaceuticals Reports:
Monoclonal Antibody Therapeutics Market Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market Size by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029
Custom Antibody Market by Service (Development, Purification, Fragmentation, Labeling), Type (mAbs, pAbs, rAbs), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology, Infectious, CVD) - Global Forecast to 2029
About MarketsandMarkets
MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.
MarketsandMarkets SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/antibody-therapeutics-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/antibody-therapeutics.asp
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/antibody-therapeutics-market-worth-597-1-billion-by-2035---exclusive-report-by-marketsandmarkets-302836116.html
